Compounds > trimethoprim--sulfamethoxazole-drug-combination

trimethoprim--sulfamethoxazole-drug-combination and Meningeal-Neoplasms

trimethoprim--sulfamethoxazole-drug-combination has been researched along with Meningeal-Neoplasms* in 2 studies

Reviews

1 review(s) available for trimethoprim--sulfamethoxazole-drug-combination and Meningeal-Neoplasms

Article	Year
Meningitis due to Xanthomonas maltophilia: case report and review. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1994, Volume: 19, Issue:2 Xanthomonas maltophilia is being increasingly recognized as an opportunistic pathogen in debilitated patients. We report a case of postoperative meningitis due to X. maltophilia and review the cases of X. maltophilia meningitis reported in the literature. Because X. maltophilia is often resistant to multiple beta-lactam agents, including cephalosporins and imipenem, trimethoprim-sulfamethoxazole appears to be the drug of choice for treatment of X. maltophilia meningitis. Topics: Cerebrospinal Fluid; Gram-Negative Bacterial Infections; Humans; Hydrocephalus; Male; Meningeal Neoplasms; Meningioma; Meningitis, Bacterial; Middle Aged; Postoperative Complications; Trimethoprim, Sulfamethoxazole Drug Combination; Ventriculoperitoneal Shunt; Xanthomonas	1994

Article

Year

Meningitis due to Xanthomonas maltophilia: case report and review.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1994, Volume: 19, Issue:2

Xanthomonas maltophilia is being increasingly recognized as an opportunistic pathogen in debilitated patients. We report a case of postoperative meningitis due to X. maltophilia and review the cases of X. maltophilia meningitis reported in the literature. Because X. maltophilia is often resistant to multiple beta-lactam agents, including cephalosporins and imipenem, trimethoprim-sulfamethoxazole appears to be the drug of choice for treatment of X. maltophilia meningitis.

Topics: Cerebrospinal Fluid; Gram-Negative Bacterial Infections; Humans; Hydrocephalus; Male; Meningeal Neoplasms; Meningioma; Meningitis, Bacterial; Middle Aged; Postoperative Complications; Trimethoprim, Sulfamethoxazole Drug Combination; Ventriculoperitoneal Shunt; Xanthomonas

1994

Trials

1 trial(s) available for trimethoprim--sulfamethoxazole-drug-combination and Meningeal-Neoplasms

Article	Year
Intensive therapy for children with acute lymphoblastic leukaemia and unfavourable presenting features. Early conclusions of study CCG-106 by the Childrens Cancer Study Group. Lancet (London, England), 1988, Oct-22, Volume: 2, Issue:8617 229 children with acute lymphoblastic leukaemia (ALL) and with clinical and laboratory features associated with a high risk of treatment failure entered a randomised study of three treatment regimens. Before 1981, such patients had a 3-year event-free survival (EFS) of 47%. Two intensive therapies, the Berlin-Frankfurt-Munster (BFM) 76/79 regimen and the New York (NY) regimen were compared with a control regimen that had achieved the best outcome in previous Trials. Data on 214 cases (93.4%) were analysed. The 3-year EFS was 78% for the BFM and NY regimens and 49% for the control regimen, a significant difference. The differences persisted after stratification by age at onset, sex, white blood cell count at diagnosis, and marrow blast morphology. Control patients were 2.7 times more likely to fail induction, to die, or to relapse than were patients on the intensive regimens. Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Drug Combinations; Female; Humans; Infant; Male; Meningeal Neoplasms; Mercaptopurine; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Radiotherapy Dosage; Sulfamethoxazole; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination	1988

Article

Year

Intensive therapy for children with acute lymphoblastic leukaemia and unfavourable presenting features. Early conclusions of study CCG-106 by the Childrens Cancer Study Group.

Lancet (London, England), 1988, Oct-22, Volume: 2, Issue:8617

229 children with acute lymphoblastic leukaemia (ALL) and with clinical and laboratory features associated with a high risk of treatment failure entered a randomised study of three treatment regimens. Before 1981, such patients had a 3-year event-free survival (EFS) of 47%. Two intensive therapies, the Berlin-Frankfurt-Munster (BFM) 76/79 regimen and the New York (NY) regimen were compared with a control regimen that had achieved the best outcome in previous Trials. Data on 214 cases (93.4%) were analysed. The 3-year EFS was 78% for the BFM and NY regimens and 49% for the control regimen, a significant difference. The differences persisted after stratification by age at onset, sex, white blood cell count at diagnosis, and marrow blast morphology. Control patients were 2.7 times more likely to fail induction, to die, or to relapse than were patients on the intensive regimens.

Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Drug Combinations; Female; Humans; Infant; Male; Meningeal Neoplasms; Mercaptopurine; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Radiotherapy Dosage; Sulfamethoxazole; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination

1988